Company: AEMD
Filing Date: 2025-04-18
Form Type: DEF 14A
Source: 0001683168-25-002685
Chunk: 14

Company: AETHLON MEDICAL INC
Filing Date: 2025-04-18
Form: DEF 14A
Chunk 14
---
                                            |
| (4)  | Consists of (i) 238 shares of common stock and (ii) 22,191 shares subject                                                             
 to stock options that are currently exercisable or will be exercisable within 60 days of April 3, 2025.                               |
| (5)  | Consists of (i) 39,070 shares of common stock.                                                                                        |
| (6)  | Consists of (i) 31,375 shares of common stock.                                                                                        |
| (7)  | Consists of (i) 49,660 shares of common stock.                                                                                        |
| (8)  | Consists of (i) 1,791 shares of common stock. Dr. Cipriani’s employment                                                               
 with us terminated on October 3, 2024.                                                                                                |
| (9)  | Consists of 21,238 shares subject to stock options that are currently                                                                 
 exercisable or will be exercisable within 60 days of April 3, 2025.                                                                   |
| (10) | Consists of (i) 31,462 shares of common stock.                                                                                        |
| (11) | Consists of the shares described in Notes (3) through (11) above, less                                                                
 the 1,957 shares of common stock held by Dr. Cipriani’s, whose employment with us terminated on October 3, 2024.                      |

| 7 |

<div align='center'>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</div>

The following describes all transactions since April
1, 2022, and all proposed transactions, in which we were or are to be a participant and the amount involved exceeds the lesser of $120,000
or one percent of the average of our total assets at year-end for the last two completed fiscal years, and in which any related person
had or will have a direct or indirect material interest. In making such decisions our Audit Committee considers and approves or disapproves
any related party transaction as defined under SEC Regulation Item 404, to the extent required by SEC regulations.

Separation Agreement with Former CEO

In connection with Charles J. Fisher, Jr. M.D.’s
resignation as the Company’s Chief Executive Officer, effective November 2023 (the “Separation Date”), in accordance
with the terms of his Executive Employment Agreement with the Company, dated as of October 30, 2020 (